The Oncology Data Network (ODN): Methodology, Challenges and Achievements.

@article{Woolmore2020TheOD,
  title={The Oncology Data Network (ODN): Methodology, Challenges and Achievements.},
  author={Ashley Woolmore and Dirk Arnold and Jean Yves Blay and Christian Buske and Alfredo Carrato and Winald R. Gerritsen and Marc Peeters and Jes{\'u}s Garc{\'i}a-Foncillas and David J Kerr},
  journal={The oncologist},
  year={2020}
}
Open to all European cancer centers, all cancer patients, and all cancer types, the Oncology Data Network (ODN) aims to create an extensive infrastructure of real‐world cancer care information. This article describes the ODN's methodological approaches, challenges, and achievements to date. 
View on PubMed
ncbi.nlm.nih.gov
3 Citations

Figures and Tables from this paper

3 Citations

Identifying options for oncology therapy regimen codification to improve standardization—combined results of an expert panel and a review

This review gives an overview of attempts to standardize chemotherapy nomenclature described in the literature, as well as of previously published identified gaps in regimen codification.

Pilot study of a European oncology regimen reference library and matching algorithm

ESOP’s validation of the matching algorithm and approach to curating a master library provides confidence in their utility for reliable comparison of real-world regimen usage across Europe.

Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France

Personalized Reimbursement Model platform enabled building a national database generating on demand Real-World Evidence based on EPR, and enabled the first performance-based risk-sharing arrangements based on PRM data, between the CEPS and Roche, for atezolizumab cancer immunotherapy in metastatic non-small cell lung cancer indication.

References

SHOWING 1-10 OF 20 REFERENCES

ASCO's approach to a learning health care system in oncology.

The promise of emerging science and the challenges confronting today's health care system can both be addressed by fully embracing the IoM's vision of a learning health care system. ASCO's initial…

Cancer Core Europe: A translational research infrastructure for a European mission on cancer

Together, Cancer Core Europe and Cancer Prevention Europe are prepared to function as a central engine to tackle, in collaboration with various partners, a potential ‘mission on cancer’ addressing the cancer burden.

The European Cancer Patient’s Bill of Rights, update and implementation 2016

This implementation phase of the European Cancer Patient’s Bill of Rights confirms the following three patient-centred principles that underpin this initiative: The right of every European citizen to receive the most accurate information and to be proactively involved in his/her care, underpinned by research and innovation.

Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement.

Five overarching recommendations to enhance the role of observational research in clinical decision making are identified: improve the quality of electronic health data available for research, improve interoperability and the exchange of Electronic health information, ensure the use of rigorous observational research methodologies, promote transparent reporting of observationalResearch studies, and protect patient privacy.

Relevance of randomised controlled trials in oncology.

General data protection regulation

Presentacio sobre l'Oficina de Proteccio de Dades Personals de la UAB i la politica Open Science. Va formar part de la conferencia "Les politiques d'Open Data / Open Acces: Implicacions a la recerca"…

The Oncology Data Network (ODN): A Collaborative European Data‐Sharing Platform to Inform Cancer Care

The progress to date and calls for greater collaboration in the Oncology Data Network are described.

RE3 A PROPOSED, SCALABLE APPROACH TO IMPLEMENTING INNOVATIVE PAYMENT AGREEMENTS

Paths to Precision Medicine – a perspective

European Federation of Pharmaceutical Industries and Associations